Cleveland Clinic Foundation, Cleveland, OH
Ramsha Ahmed , Michael Sheu , Wei Wei , Moshe Chaim Ornstein , Timothy D. Gilligan , Danai Dima , Steven Campbell , Byron H Lee , Christopher Weight , Christopher Eing Wee , Omar Y. Mian , Jihad Kaouk , Georges-Pascal Haber , Shilpa Gupta
Background: Upper tract urothelial carcinoma (UTUC) is a rare and heterogeneous disease accounting for approximately 5-10% of UC. While tumor grade and stage are known prognostic factors, data on other factors affecting outcomes in UTUC patients (pts) undergoing surgery is scant. We studied effect of various clinical factors and treatment on outcomes in UTUC. Methods: This is a single-institution retrospective study of 607 pts with UTUC undergoing surgery (nephroureterectomy (NU) or ureterectomy (U)) between Jan 2000 and Dec 2020. We studied effect of demographics, clinicopathological features, tumor location, preoperative Neutrophil-to-Lymphocyte ratio (NLR) and Albumin-to-Globulin ratio (AGR) and use of neoadjuvant or adjuvant chemotherapy on overall survival (OS) and recurrence free survival (RFS). Results: Of the 607 pts 401 (66.06%) were males and 355 (58.48%) were > 70 yrs; 232 pts (38.22%) had UTUC of renal pelvis, 242 (39.87%) of ureter and 133 (21.91%) of both. 542 pts (89.29%) underwent radical NU and 65 (10.71%) segmental U; 328 patients (54.04%) were diagnosed with muscle invasive UC (MIUC) ( > / = pT2) and 276 (45.47%) with non-MIUC ( < / = pT2). Only 51 (8.4%) pts had lymph node positive (N+) disease. Lymphovascular invasion (LVI) was identified in 163 (26.85%) and carcinoma- in-situ (CIS) in 163 (26.85%) pts. Surgical margins were positive in 92 pts (15.16%). Median NLR cutoff was 3.25 and AGR cutoff was 1.25 (dichotomized based on literature). 44 pts (7.2%) received Neoadjuvant chemotherapy and 49 pts (8%) received adjuvant chemotherapy. Tumor recurrence occurred in 216 pts (35.58%) of which 65% were at urothelial and 35% at non-urothelial sites. With median follow up of 35.2 mos, median OS was 82.69 mos and 5-yr OS rate was 60%; median RFS was 29.47 mos and 5-yr RFS rate was 40%. High grade, age > / = 70 yrs, high NLR, low AGR, presence of LVI, positive margins, CIS, MIUC, N+ disease were associated with worse outcomes. Pts with only renal pelvis involvement had better OS. Conclusions: In this large, long term follow-up series of UTUC pts, we identified several prognostic factors besides grade and stage that impact outcomes. These findings warrant further validation for use in clinical practice.
Prognostic Factors | Median OS (mos) | Median RFS (mos) |
---|---|---|
Age, > / = 70 vs < 70 yrs | 48.3 vs 130.56 (p < 0.0001) | 20.5 vs 70.2 (p < 0.0001) |
LVI (+ vs -) | 29.7 vs 98.63 (p < 0.0001) | 12.2 vs 45.5 (p < 0.0001) |
Margins (+ vs -) | 30.49 vs 90.09 (p < 0.0001) | 18.9 vs 32.6 (p = 0.01) |
Tumor site (renal pelvis; renal pelvis+ureter; ureter) | 108.06; 61.01; 81.51 (p = 0.01) | 33.6; 25.1; 27.04 (p = 0.3) |
Muscle invasion (+ vs -) | 48.8 vs109.6 (p < 0.0001) | 17.8 vs 61 (p < 0.0001) |
N+ vs N- disease | 22.7 vs 84.7 (p < 0.0001) | 10 vs 32.6 (p = 0.003) |
CIS (+ vs -) | 71.8 vs 89.6 (p = 0.02) | 24.1 vs 32.13 (p = 0.127) |
NLR > / = 3.25 vs < 3.25 | 69.5 vs112.8 (p = 0.003) | 27.2 vs 37 (p = 0.123) |
AGR > / = 1.25 vs < 1.25 | 84.7 vs 51.4 (p = 0.0003) | 33.6 vs 17.2 (p = 0.0037) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Genitourinary Cancers Symposium
First Author: Helen Gao
2023 ASCO Annual Meeting
First Author: Xiaojian Yang
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Bahar Laderian
2023 ASCO Annual Meeting
First Author: Robin Park